Modified GRF 1-29 (also abbreviated as Mod GRF 1-29), is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH). It is a modified version of the first twenty-nine amino acids of the naturally occurring GHRH. This modification has been suggested to provide better stability and potentially reduce metabolic clearance. More specifically, the modifications may involve the substitution of four specific amino acids within the initial 29 amino acids of Growth Hormone-Releasing Hormone (GHRH). These changes occur at the 2nd, 8th, 15th, and 27th positions and may potentially enhance the peptide’s durability against enzymatic degradation, especially by enzymes such as dipeptidyl peptidase-4 (DPP-4). It is hypothesized that replacing L-alanine with D-alanine at the second position may increase resistance to molecular breakdown. Furthermore, replacing asparagine with glutamine at the eighth position might reduce the likelihood of asparagine reconfiguration and amide hydrolysis. Additionally, substituting glycine with alanine at the 15th position may improve bioactivity. Lastly, the switch from methionine to leucine at the 27th position is thought to help prevent methionine oxidation. It may lead to natural growth hormone production and increased levels of IGF-1 (Insulin-Like Growth Factor-1).[1]
GHRP-2 (Growth Hormone Releasing Peptide) is a second-generation GHRP, a type of Growth Hormone Secretagogue. Other examples include GHRP-6, Ipamorelin, and Hexarelin, among others. It has been studied for its potential to increase growth hormone production by activating the receptors for the hunger hormone, ghrelin.[2]
Various peptides have been studied regarding their potential to increase endogenous GH production. None have been lauded as inducing significant impact, primarily attributed to their apparent short-term activity. However, Modified GRF 1-29, or Mod GRF 1-29, is classified as a growth hormone peptide, which researchers suggest may have the potential to provide a prolonged increase in the peak and basal growth hormone levels. Like the natural Growth Hormone Release Hormone (GHRH), this peptide appears to act by binding to the growth hormone-releasing hormone receptors in the pituitary gland. A negative feedback mechanism by Somatostatin appears to regulate any Modified GRF 1-29 action on growth hormone release. It may potentially prevent excessive hormone secretion and sustain a natural pattern of growth hormone concentration.
Reviews
There are no reviews yet.